Valeant Reports 41% Increase in Second-Quarter Revenue

Valeant Pharmaceuticals International Inc. raised its forecast for full-year earnings after posting a 41 percent increase in second-quarter revenue.

Valeant estimates 2013 adjusted earnings per share of $6 to $6.20, up from a prediction in May of $5.55 to $5.85. Second-quarter revenue excluding one-time items rose to $1.1 billion, the company said today in a statement.

Cash earnings per share increased 54 percent, excluding one-time items, in the second-quarter to $1.34, the company said. Analysts had estimated an EPS of $1.28, according to a survey compiled by Bloomberg.

Before it's here, it's on the Bloomberg Terminal.